BioSpace News Archive

vTv Therapeutics Inc. today announced that Deepa Prasad will lead the company as President and Chief Executive Officer, effective immediately.

Maryland Oncology Hematology (MOH) at the Aquilino Cancer Center today announces promising topline data from its open-label study of psilocybin therapy to treat depression in cancer patients.

BUCHA BIO INC. oversubscribed to raise $550K as part of the New York-based company’s latest fundraising.

STAAR Surgical Company today announced that it will release financial results for the third quarter ended October 1, 2021 on Wednesday, November 3, 2021 after the market close.

Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced the completion of patient enrollment in the Pridopidine Outcome On Function in Huntington’s Disease (PROOF-HD) global Phase 3 clinical trial.

Axalbion today announced that the first patients have been treated in a Phase 2 clinical study in chronic cough with AX-8, its lead compound. AX-8 is a potent and selective oral agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel.

Chase Therapeutics Corporation today announced the completion of a milestone-based $20M Series B financing led by Chinalink Asia Holdings of Hong Kong.

InHealth Technologies, maker of Blom-Singer® voice restoration and ENT products and a business unit of Freudenberg Medical, announces the commercial launch of Blom-Singer® SpeakFree™ HME Hands Free Valve created for people who have undergone a total laryngectomy.

Plinabulin’s anti-cancer effects were tested against approximately 80 patient-derived tumor models with small cell lung cancer (SCLC) tumor types being the most sensitive to plinabulin monotherapy at IC 70 of 35 nM

Hardy Diagnostics is pleased to announce its release of HardyCHROM™ Candida + auris, a chromogenic media recommended for the selective isolation and differential identification of Candida species.